董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christian Henry | 男 | Director | 58 | 33.19万美元 | 5.63 | 2025-12-18 |
| Kathy Hopinkah Hannan | 女 | Director | 64 | 2.91万美元 | 未持股 | 2025-12-18 |
| Shyam Sankar | 男 | chair | 44 | 36.34万美元 | 10.43 | 2025-12-18 |
| Jason Kelly | -- | Chief Executive Officer,Founder and Director | 45 | 570.90万美元 | 235.79 | 2025-12-18 |
| Reshma Shetty | -- | President,Founder and Director | 45 | 347.94万美元 | 487.23 | 2025-12-18 |
| Ross Fubini | 男 | Director | 50 | 31.74万美元 | 5.51 | 2025-12-18 |
| Sri Kosuri | 男 | Director | -- | 30.71万美元 | 8.65 | 2025-12-18 |
| Myrtle Potter | 女 | Director | -- | 未披露 | 未持股 | 2025-12-18 |
| Harry E. Sloan | 男 | Director | 75 | 31.71万美元 | 30.34 | 2025-12-18 |
| Myrtle Potter | 女 | Director | 67 | 2.69万美元 | 未持股 | 2025-12-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jason Kelly | -- | Chief Executive Officer,Founder and Director | 45 | 570.90万美元 | 235.79 | 2025-12-18 |
| Reshma Shetty | -- | President,Founder and Director | 45 | 347.94万美元 | 487.23 | 2025-12-18 |
| Steven Coen | 男 | Chief Financial Officer | 59 | 133.23万美元 | 5.13 | 2025-12-18 |
董事简历
中英对照 | 中文 | 英文- Christian Henry
-
Christian Henry自2016年11月起担任董事，自2017年10月起担任董事会主席。Henry先生还担任Ginkgo Bioworks（一家私人合成生物学公司）和Pacific Biosciences（一家上市的生命科学公司）的董事会成员。Henry先生曾于2015年至2017年1月担任Illumina，Inc.执行Vice President兼首席商务官，此前曾于2014年至2015年担任高级副总裁兼首席商务官，2012年至2014年担任高级副总裁基因组解决方案总经理高级副总裁，2010年至2012年，担任生命科学首席财务官和总经理；2009年至2010年，担任企业发展和首席财务官高级副总裁，；2007年至2009年，担任高级副总裁和首席财务官；2005年至2006年，担任Vice President和首席财务官。在加入Illumina，Inc.之前，Henry先生从2003年到2005年担任Tickets.com，Inc.的首席财务官。从1999年到2003年，Henry先生担任赛默飞世尔科技（Thermo Fisher Scientific）于2016年收购的Affymetrix，Inc.的Vice President、财务与公司财务总监。1997年，Henry先生加入Nektar Therapeutics（前身为Inhale Therapeutic Systems，Inc.），担任公司财务总监，后来从1997年到1999年担任其首席会计官。Henry先生于1996年担任Sugen，Inc.的总会计经理。他的职业生涯始于1992年任职Ernst&Young LLP，在那里他曾担任高级会计师（直到1996年）。Henry先生在加州大学圣地亚哥分校（University of California，San Diego）获得生物化学和细胞生物学学士学位，并在加州大学欧文分校（University of California，Irvine）获得金融工商管理硕士学位。
Christian Henry,has served as a director since November 2016, and as Chairman of Wave Life Sciences Ltd. Board since October 2017. Mr. Henry currently serves as the President and Chief Executive Officer of Pacific Biosciences, a publicly traded life sciences company, a position he has held since September 2020, and has also served on its board of directors since 2018. Mr. Henry has served on the board of directors of Ginkgo Bioworks, a publicly-traded synthetic biology company, since 2016, and previously served on the board of directors CM Life Sciences III Inc., a publicly-traded special purpose acquisition company, from April 2021 through December 2021. Mr. Henry served as Executive Vice President & Chief Commercial Officer of Illumina, Inc. from 2015 through January 2017, and previously served as Senior Vice President & Chief Commercial Officer from 2014 to 2015, Senior Vice President & General Manager Genomic Solutions from 2012 to 2014, Senior Vice President, Chief Financial Officer & General Manager Life Sciences from 2010 to 2012, Senior Vice President, Corporate Development & Chief Financial Officer from 2009 to 2010, Senior Vice President & Chief Financial Officer from 2007 to 2009, and Vice President & Chief Financial Officer from 2005 to 2006. Prior to joining Illumina, Inc., Mr. Henry served as the Chief Financial Officer of Tickets.com, Inc. from 2003 to 2005. From 1999 to 2003, Mr. Henry served as Vice President, Finance & Corporate Controller of Affymetrix, Inc. (acquired by Thermo Fisher Scientific in 2016). In 1997, Mr. Henry joined Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.), as Corporate Controller, and later as its Chief Accounting Officer from 1997 to 1999. In 1996, Mr. Henry served as General Accounting Manager of Sugen, Inc. Mr. Henry began his career in 1992 at Ernst & Young LLP, where he was a Senior Accountant through 1996. Mr. Henry earned his B.A. in biochemistry and cell biology from the University of California, San Diego, and his M.B.A., with a concentration in finance, from the University of California, Irvine. - Christian Henry自2016年11月起担任董事，自2017年10月起担任董事会主席。Henry先生还担任Ginkgo Bioworks（一家私人合成生物学公司）和Pacific Biosciences（一家上市的生命科学公司）的董事会成员。Henry先生曾于2015年至2017年1月担任Illumina，Inc.执行Vice President兼首席商务官，此前曾于2014年至2015年担任高级副总裁兼首席商务官，2012年至2014年担任高级副总裁基因组解决方案总经理高级副总裁，2010年至2012年，担任生命科学首席财务官和总经理；2009年至2010年，担任企业发展和首席财务官高级副总裁，；2007年至2009年，担任高级副总裁和首席财务官；2005年至2006年，担任Vice President和首席财务官。在加入Illumina，Inc.之前，Henry先生从2003年到2005年担任Tickets.com，Inc.的首席财务官。从1999年到2003年，Henry先生担任赛默飞世尔科技（Thermo Fisher Scientific）于2016年收购的Affymetrix，Inc.的Vice President、财务与公司财务总监。1997年，Henry先生加入Nektar Therapeutics（前身为Inhale Therapeutic Systems，Inc.），担任公司财务总监，后来从1997年到1999年担任其首席会计官。Henry先生于1996年担任Sugen，Inc.的总会计经理。他的职业生涯始于1992年任职Ernst&Young LLP，在那里他曾担任高级会计师（直到1996年）。Henry先生在加州大学圣地亚哥分校（University of California，San Diego）获得生物化学和细胞生物学学士学位，并在加州大学欧文分校（University of California，Irvine）获得金融工商管理硕士学位。
- Christian Henry,has served as a director since November 2016, and as Chairman of Wave Life Sciences Ltd. Board since October 2017. Mr. Henry currently serves as the President and Chief Executive Officer of Pacific Biosciences, a publicly traded life sciences company, a position he has held since September 2020, and has also served on its board of directors since 2018. Mr. Henry has served on the board of directors of Ginkgo Bioworks, a publicly-traded synthetic biology company, since 2016, and previously served on the board of directors CM Life Sciences III Inc., a publicly-traded special purpose acquisition company, from April 2021 through December 2021. Mr. Henry served as Executive Vice President & Chief Commercial Officer of Illumina, Inc. from 2015 through January 2017, and previously served as Senior Vice President & Chief Commercial Officer from 2014 to 2015, Senior Vice President & General Manager Genomic Solutions from 2012 to 2014, Senior Vice President, Chief Financial Officer & General Manager Life Sciences from 2010 to 2012, Senior Vice President, Corporate Development & Chief Financial Officer from 2009 to 2010, Senior Vice President & Chief Financial Officer from 2007 to 2009, and Vice President & Chief Financial Officer from 2005 to 2006. Prior to joining Illumina, Inc., Mr. Henry served as the Chief Financial Officer of Tickets.com, Inc. from 2003 to 2005. From 1999 to 2003, Mr. Henry served as Vice President, Finance & Corporate Controller of Affymetrix, Inc. (acquired by Thermo Fisher Scientific in 2016). In 1997, Mr. Henry joined Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.), as Corporate Controller, and later as its Chief Accounting Officer from 1997 to 1999. In 1996, Mr. Henry served as General Accounting Manager of Sugen, Inc. Mr. Henry began his career in 1992 at Ernst & Young LLP, where he was a Senior Accountant through 1996. Mr. Henry earned his B.A. in biochemistry and cell biology from the University of California, San Diego, and his M.B.A., with a concentration in finance, from the University of California, Irvine.
- Kathy Hopinkah Hannan
-
Kathy Hopinkah Hannan，毕马威会计师事务所全球首席合伙人、董事会领导中心高级顾问和国家领导人全面影响战略，2015-2018年。毕马威会计师事务所多元化和企业责任国家管理合伙人，2009-2015年。毕马威会计师事务所中西部地区税务服务管理合伙人，2004-2009年。毕马威会计师事务所人力资源副主席，2000-2004。
Kathy Hopinkah Hannan has over 25 years of executive leadership experience spanning global finance, human capital strategy, enterprise risk and corporate governance. She has helped multinational organizations navigate regulatory compliance, operational transformation, supply chain optimization and strategic change while sustaining performance and strengthening resilience. Her breadth of experience supports the Board's oversight of Otis' global growth strategy, disciplined financial management, risk governance and long term talent priorities. - Kathy Hopinkah Hannan，毕马威会计师事务所全球首席合伙人、董事会领导中心高级顾问和国家领导人全面影响战略，2015-2018年。毕马威会计师事务所多元化和企业责任国家管理合伙人，2009-2015年。毕马威会计师事务所中西部地区税务服务管理合伙人，2004-2009年。毕马威会计师事务所人力资源副主席，2000-2004。
- Kathy Hopinkah Hannan has over 25 years of executive leadership experience spanning global finance, human capital strategy, enterprise risk and corporate governance. She has helped multinational organizations navigate regulatory compliance, operational transformation, supply chain optimization and strategic change while sustaining performance and strengthening resilience. Her breadth of experience supports the Board's oversight of Otis' global growth strategy, disciplined financial management, risk governance and long term talent priorities.
- Shyam Sankar
-
Shyam Sankar自2006年以来担任Palantir Technologies Inc.首席运营官和执行副总裁，一直担任Palantir Technologies Inc.的各种职位。Sankar先生拥有康奈尔大学电气与计算机工程学士学位，斯坦福大学管理科学与工程硕士学位。
Shyam Sankar has served in various positions with Palantir Technologies Inc. since 2006, most recently as Palantir Technologies Inc. Chief Technology Officer ("CTO") and Executive Vice President. Mr. Sankar holds a B.S. in Electrical and Computer Engineering from Cornell University and a M.S. in Management Science & Engineering from Stanford University. - Shyam Sankar自2006年以来担任Palantir Technologies Inc.首席运营官和执行副总裁，一直担任Palantir Technologies Inc.的各种职位。Sankar先生拥有康奈尔大学电气与计算机工程学士学位，斯坦福大学管理科学与工程硕士学位。
- Shyam Sankar has served in various positions with Palantir Technologies Inc. since 2006, most recently as Palantir Technologies Inc. Chief Technology Officer ("CTO") and Executive Vice President. Mr. Sankar holds a B.S. in Electrical and Computer Engineering from Cornell University and a M.S. in Management Science & Engineering from Stanford University.
- Jason Kelly
-
Jason Kelly，我们的创始人之一，自2008年成立以来担任我们的董事会成员和首席执行官。Kelly博士曾担任CM Life Sciences IIInc.董事纳斯达克:CMII，一家专注于生命科学领域的特殊目的收购公司，自2021年2月首次公开募股以来。Kelly博士拥有麻省理工学院生物工程博士学位和化学工程和生物学学士学位。
Jason Kelly,one of our founders, has served as a member of our board of directors and as the Chief Executive Officer since Ginkgo’s founding in 2008. Dr. Kelly has served as a director of CM Life Sciences II Inc. Nasdaq: CMII, a special purpose acquisition company with a focus on the life sciences sector, since its initial public offering in February 2021. Dr. Kelly has a Ph.D. in Biological Engineering and a B.S. in Chemical Engineering and Biology from the Massachusetts Institute of Technology. - Jason Kelly，我们的创始人之一，自2008年成立以来担任我们的董事会成员和首席执行官。Kelly博士曾担任CM Life Sciences IIInc.董事纳斯达克:CMII，一家专注于生命科学领域的特殊目的收购公司，自2021年2月首次公开募股以来。Kelly博士拥有麻省理工学院生物工程博士学位和化学工程和生物学学士学位。
- Jason Kelly,one of our founders, has served as a member of our board of directors and as the Chief Executive Officer since Ginkgo’s founding in 2008. Dr. Kelly has served as a director of CM Life Sciences II Inc. Nasdaq: CMII, a special purpose acquisition company with a focus on the life sciences sector, since its initial public offering in February 2021. Dr. Kelly has a Ph.D. in Biological Engineering and a B.S. in Chemical Engineering and Biology from the Massachusetts Institute of Technology.
- Reshma Shetty
-
Reshma Shetty，我们的创始人之一，自2008年成立以来担任我们的董事会成员，总裁兼首席运营官。谢蒂博士目前在非营利组织“核威胁倡议”的生物咨询小组任职。谢蒂博士拥有麻省理工学院生物工程博士学位和犹他大学计算机科学学士学位。
Reshma Shetty,one of our founders, has served as a member of our board of directors and as President and Chief Operating Officer since Ginkgo’s founding in 2008. Dr. Shetty currently serves on the Bio Advisory Group at the non-profit Nuclear Threat Initiative. Dr. Shetty has a Ph.D. in Biological Engineering from the Massachusetts Institute of Technology and a B.S. in Computer Science from the University of Utah. - Reshma Shetty，我们的创始人之一，自2008年成立以来担任我们的董事会成员，总裁兼首席运营官。谢蒂博士目前在非营利组织“核威胁倡议”的生物咨询小组任职。谢蒂博士拥有麻省理工学院生物工程博士学位和犹他大学计算机科学学士学位。
- Reshma Shetty,one of our founders, has served as a member of our board of directors and as President and Chief Operating Officer since Ginkgo’s founding in 2008. Dr. Shetty currently serves on the Bio Advisory Group at the non-profit Nuclear Threat Initiative. Dr. Shetty has a Ph.D. in Biological Engineering from the Massachusetts Institute of Technology and a B.S. in Computer Science from the University of Utah.
- Ross Fubini
-
Ross Fubini预计将在本次发行结束时担任董事。Ross Fubini是一位早期技术投资者。Fubini先生自2017年以来创立了风险投资公司XYZ Ventures，并一直担任其董事总经理。他还于2017年联合创立了全球投资公司Village Global。Fubini先生是BeyondHQ，Piazza Technologies，Legion，Beneficial State Bank，Liferaft Risk Technologies，Inc.，Saltbox，Inc.，Oro Labs，Inc.，Auxilius Inc.，Pebble Health Inc.，Bureau Inc.，Sardine，Inc.和Smash的董事会成员。富比尼的投资包括Lendup、Optimizely和Metromile NASDAQ:MILE。任职XYZ公司之前，他曾担任Canaan Partners公司的合伙人（从2012年到2015年）、Kapor Capital公司（从2011年到2012年），在那里他曾专注于企业应用程序、金融科技和医疗保健IT空间的可防御业务。Fubini先生共同创立并发展了Cubetree，这是一家高德纳有远见的企业社会协作公司。2010年Cubetree被SuccessFactors（原NYSE:SFSF，现为SAP公司）收购后，Fubini先生担任SuccessFactors的副总裁。Fubini先生还在赛门铁克（原纳斯达克代码:SYMC），BEA/Plumtree（原纳斯达克代码:PLUM），Tellme Networks和Netscape（原纳斯达克代码:NSCP）担任工程领导职务。他拥有卡内基梅隆大学的工程和艺术学士学位。
Ross Fubini,has served as a director since October 2021. Mr. Fubini is an early stage technology investor. Mr. Fubini founded and has served as Managing Director of XYZ Ventures, a venture capital investment firm since 2017. He also co-founded Village Global, a global investment firm, in 2017. Mr. Fubini is a board member of BeyondHQ, Piazza Technologies, Legion, Beneficial State Bank, LifeRaft Risk Technologies, Inc., Saltbox, Inc., Oro Labs, Inc., Auxilius Inc., Pebble Health Inc., Bureau Inc., Sardine, Inc. and Smash. Mr. Fubini's investments include Lendup, Optimizely, and Metromile (NASDAQ: MILE). Prior to XYZ, Mr. Fubini was a partner at Canaan Partners from 2012 to 2015, and Kapor Capital from 2011 to 2012, where he focused on defensible businesses across enterprise applications, FinTech and healthcare IT spaces. Mr. Fubini co-founded and grew CubeTree, a Gartner Visionary enterprise social collaboration company. After CubeTree was acquired by SuccessFactors (formerly NYSE: SFSF, now an SAP company) in 2010, Mr. Fubini served as a vice president of Success Factors. Mr. Fubini also held engineering leadership roles at Symantec (formerly NASDAQ: SYMC), BEA/Plumtree (formerly NASDAQ: PLUM), TellMe Networks, and Netscape (formerly NASDAQ: NSCP). He holds a Bachelor's Degree in Engineering and Art from Carnegie Mellon University. - Ross Fubini预计将在本次发行结束时担任董事。Ross Fubini是一位早期技术投资者。Fubini先生自2017年以来创立了风险投资公司XYZ Ventures，并一直担任其董事总经理。他还于2017年联合创立了全球投资公司Village Global。Fubini先生是BeyondHQ，Piazza Technologies，Legion，Beneficial State Bank，Liferaft Risk Technologies，Inc.，Saltbox，Inc.，Oro Labs，Inc.，Auxilius Inc.，Pebble Health Inc.，Bureau Inc.，Sardine，Inc.和Smash的董事会成员。富比尼的投资包括Lendup、Optimizely和Metromile NASDAQ:MILE。任职XYZ公司之前，他曾担任Canaan Partners公司的合伙人（从2012年到2015年）、Kapor Capital公司（从2011年到2012年），在那里他曾专注于企业应用程序、金融科技和医疗保健IT空间的可防御业务。Fubini先生共同创立并发展了Cubetree，这是一家高德纳有远见的企业社会协作公司。2010年Cubetree被SuccessFactors（原NYSE:SFSF，现为SAP公司）收购后，Fubini先生担任SuccessFactors的副总裁。Fubini先生还在赛门铁克（原纳斯达克代码:SYMC），BEA/Plumtree（原纳斯达克代码:PLUM），Tellme Networks和Netscape（原纳斯达克代码:NSCP）担任工程领导职务。他拥有卡内基梅隆大学的工程和艺术学士学位。
- Ross Fubini,has served as a director since October 2021. Mr. Fubini is an early stage technology investor. Mr. Fubini founded and has served as Managing Director of XYZ Ventures, a venture capital investment firm since 2017. He also co-founded Village Global, a global investment firm, in 2017. Mr. Fubini is a board member of BeyondHQ, Piazza Technologies, Legion, Beneficial State Bank, LifeRaft Risk Technologies, Inc., Saltbox, Inc., Oro Labs, Inc., Auxilius Inc., Pebble Health Inc., Bureau Inc., Sardine, Inc. and Smash. Mr. Fubini's investments include Lendup, Optimizely, and Metromile (NASDAQ: MILE). Prior to XYZ, Mr. Fubini was a partner at Canaan Partners from 2012 to 2015, and Kapor Capital from 2011 to 2012, where he focused on defensible businesses across enterprise applications, FinTech and healthcare IT spaces. Mr. Fubini co-founded and grew CubeTree, a Gartner Visionary enterprise social collaboration company. After CubeTree was acquired by SuccessFactors (formerly NYSE: SFSF, now an SAP company) in 2010, Mr. Fubini served as a vice president of Success Factors. Mr. Fubini also held engineering leadership roles at Symantec (formerly NASDAQ: SYMC), BEA/Plumtree (formerly NASDAQ: PLUM), TellMe Networks, and Netscape (formerly NASDAQ: NSCP). He holds a Bachelor's Degree in Engineering and Art from Carnegie Mellon University.
- Sri Kosuri
-
Sri Kosuri，自2019年以来一直担任Octant，Inc.（“Octant”）的首席执行官，该公司是一家位于加利福尼亚州埃默里维尔的私营药物发现公司。他之前是加州大学洛杉矶分校化学和生物化学系的副教授，他的实验室在那里开发了合成生物学、基因组学和生物化学方面的技术。Kosuri博士此前曾在哈佛大学WYSS研究所工作，在那里他构建了基因合成、DNA信息存储、基因编辑和大规模多重分析方面的众多技术。作为科学顾问委员会的成员，他帮助建立了Gen9，这是一家基因合成公司，后来于2017年被该公司收购，并帮助创办了Joule Unlimited，这是一家工程藻类转化为生物燃料的公司。他是Searle学者（2015年）、NIHNew Innovator（2014年），在麻省理工学院获得生物工程理学博士学位，在加州大学伯克利分校获得生物工程理学学士学位。
Sri Kosuri,has been the chief executive officer of Octant, Inc. ("Octant"), a private, drug discovery company based in Emeryville, California since 2019. He was previously an associate professor at UCLA in the Chemistry and Biochemistry Department where his lab developed technologies in synthetic biology, genomics, and biochemistry. Dr. Kosuri previously worked at the Wyss Institute at Harvard University, where he built numerous technologies in gene synthesis, DNA information storage, gene editing, and large-scale multiplexed assays. He helped build Gen9, a gene synthesis company later acquired by the Company in 2017, as a member of its scientific advisory board and helped start Joule Unlimited, an engineered algae-to-biofuel company. He is a Searle Scholar (2015), an NIH New Innovator (2014), and received his Doctor of Science in Biological Engineering at MIT and Bachelor of Science in Bioengineering at UC Berkeley. - Sri Kosuri，自2019年以来一直担任Octant，Inc.（“Octant”）的首席执行官，该公司是一家位于加利福尼亚州埃默里维尔的私营药物发现公司。他之前是加州大学洛杉矶分校化学和生物化学系的副教授，他的实验室在那里开发了合成生物学、基因组学和生物化学方面的技术。Kosuri博士此前曾在哈佛大学WYSS研究所工作，在那里他构建了基因合成、DNA信息存储、基因编辑和大规模多重分析方面的众多技术。作为科学顾问委员会的成员，他帮助建立了Gen9，这是一家基因合成公司，后来于2017年被该公司收购，并帮助创办了Joule Unlimited，这是一家工程藻类转化为生物燃料的公司。他是Searle学者（2015年）、NIHNew Innovator（2014年），在麻省理工学院获得生物工程理学博士学位，在加州大学伯克利分校获得生物工程理学学士学位。
- Sri Kosuri,has been the chief executive officer of Octant, Inc. ("Octant"), a private, drug discovery company based in Emeryville, California since 2019. He was previously an associate professor at UCLA in the Chemistry and Biochemistry Department where his lab developed technologies in synthetic biology, genomics, and biochemistry. Dr. Kosuri previously worked at the Wyss Institute at Harvard University, where he built numerous technologies in gene synthesis, DNA information storage, gene editing, and large-scale multiplexed assays. He helped build Gen9, a gene synthesis company later acquired by the Company in 2017, as a member of its scientific advisory board and helped start Joule Unlimited, an engineered algae-to-biofuel company. He is a Searle Scholar (2015), an NIH New Innovator (2014), and received his Doctor of Science in Biological Engineering at MIT and Bachelor of Science in Bioengineering at UC Berkeley.
- Myrtle Potter
-
Myrtle Potter，目前担任生命科学咨询公司Myrtle Potter公司有限责任公司的首席执行官。在此之前，她曾于2023年7月至2024年4月担任住友制药美国公司的总裁、首席执行官和董事会主席，该公司是由八家美国生物制药公司合并而成。Potter女士还曾在2019年12月至2023年6月期间担任Sumitovant Biopharma，Inc.的首席执行官，该公司是五家生物技术子公司的母公司。在此之前，她于2018年7月至2019年12月在Roivant Sciences公司担任Vant运营主席，负责监管13家生物制药公司，在11个治疗领域拥有超过30种在研药物。作为Myrtle Potter & Company，LLC的首席执行官，Potter女士和她精心挑选的专家团队领导了众多生物制药公司的重大战略努力和多个产品发布的准备工作。2000年至2004年，Potter女士在生物制药公司基因泰克担任首席运营官，2004年至2005年担任基因泰克商业运营总裁兼执行副总裁。在加入基因泰克公司之前，她曾担任多个职位，包括在百时美施贵宝担任美国心血管/代谢药总裁，以及在默沙东公司担任副总裁。在TERM2公司任职期间，她创办了Astra 默沙东，Inc.公司，该公司后来通过一系列交易，成为了阿斯利康 PLC的一部分。Potter女士目前在Guardant Health Inc.和Liberty Mutual Holding Company，Inc.的董事会以及芝加哥大学董事会任职。她此前曾于2018年9月至2023年3月在Myovant Sciences公司董事会任职，于2018年7月至2021年3月在Urovant Sciences公司董事会任职，于2017年6月至2020年6月在Axsome Therapeutics，Inc.任职，于2019年6月至2020年2月在Immunovant，于2018年9月至2020年2月在Axovant Gene Therapies，Ltd.任职，于2018年10月至2020年2月在Arbutus生物制药，Inc.任职，而亚马逊公司 Ms. Potter拥有芝加哥大学的文学学士学位。
Myrtle Potter,currently serves as the Chief Executive Officer of Myrtle Potter & Company, LLC, a life sciences advisory firm. Prior to this she served as President, Chief Executive Officer and Chairperson of the Board of Sumitomo Pharma America, Inc., from July 2023 to April 2024, which was formed through the consolidation of eight U.S. biopharmaceutical companies. Ms. Potter also served as the Chief Executive Officer of Sumitovant Biopharma, Inc., the parent company of five biotechnology subsidiaries, from December 2019 to June 2023. Prior to this, she served as Vant Operating Chair at Roivant Sciences, Inc. from July 2018 to December 2019, where she oversaw thirteen biopharmaceutical companies with over thirty investigational drugs in eleven therapeutic areas. As Chief Executive Officer of Myrtle Potter & Company, LLC, Ms. Potter and her hand-picked team of experts led major strategic efforts and the preparation for multiple product launches for numerous biopharmaceutical companies. From 2000 to 2004, Ms. Potter served as Chief Operating Officer at Genentech, Inc., a biopharmaceutical company, and from 2004 to 2005, she served as the President, Commercial Operations and Executive Vice President of Genentech. Prior to joining Genentech, she held various positions, including President, U.S. Cardiovascular/Metabolics at Bristol-Myers Squibb, and Vice President at Merck & Co. While at Merck, she started the company Astra Merck, Inc. which later, through a series of transactions, became a part of AstraZeneca PLC. Ms. Potter currently serves on the Boards of Directors of Guardant Health Inc. and Liberty Mutual Holding Company, Inc. and the Board of Trustees of The University of Chicago. She has previously served on the Boards of Directors of Myovant Sciences, Ltd. from September 2018 to March 2023, Urovant Sciences Ltd. from July 2018 to March 2021, Axsome Therapeutics, Inc. from June 2017 to June 2020, Immunovant, Inc. from June 2019 to February 2020, Axovant Gene Therapies, Ltd. from September 2018 to February 2020, and Arbutus Biopharma, Inc. from October 2018 to February 2020, and Amazon.com, Inc. Ms. Potter holds a Bachelor of Arts Degree from The University of Chicago. - Myrtle Potter，目前担任生命科学咨询公司Myrtle Potter公司有限责任公司的首席执行官。在此之前，她曾于2023年7月至2024年4月担任住友制药美国公司的总裁、首席执行官和董事会主席，该公司是由八家美国生物制药公司合并而成。Potter女士还曾在2019年12月至2023年6月期间担任Sumitovant Biopharma，Inc.的首席执行官，该公司是五家生物技术子公司的母公司。在此之前，她于2018年7月至2019年12月在Roivant Sciences公司担任Vant运营主席，负责监管13家生物制药公司，在11个治疗领域拥有超过30种在研药物。作为Myrtle Potter & Company，LLC的首席执行官，Potter女士和她精心挑选的专家团队领导了众多生物制药公司的重大战略努力和多个产品发布的准备工作。2000年至2004年，Potter女士在生物制药公司基因泰克担任首席运营官，2004年至2005年担任基因泰克商业运营总裁兼执行副总裁。在加入基因泰克公司之前，她曾担任多个职位，包括在百时美施贵宝担任美国心血管/代谢药总裁，以及在默沙东公司担任副总裁。在TERM2公司任职期间，她创办了Astra 默沙东，Inc.公司，该公司后来通过一系列交易，成为了阿斯利康 PLC的一部分。Potter女士目前在Guardant Health Inc.和Liberty Mutual Holding Company，Inc.的董事会以及芝加哥大学董事会任职。她此前曾于2018年9月至2023年3月在Myovant Sciences公司董事会任职，于2018年7月至2021年3月在Urovant Sciences公司董事会任职，于2017年6月至2020年6月在Axsome Therapeutics，Inc.任职，于2019年6月至2020年2月在Immunovant，于2018年9月至2020年2月在Axovant Gene Therapies，Ltd.任职，于2018年10月至2020年2月在Arbutus生物制药，Inc.任职，而亚马逊公司 Ms. Potter拥有芝加哥大学的文学学士学位。
- Myrtle Potter,currently serves as the Chief Executive Officer of Myrtle Potter & Company, LLC, a life sciences advisory firm. Prior to this she served as President, Chief Executive Officer and Chairperson of the Board of Sumitomo Pharma America, Inc., from July 2023 to April 2024, which was formed through the consolidation of eight U.S. biopharmaceutical companies. Ms. Potter also served as the Chief Executive Officer of Sumitovant Biopharma, Inc., the parent company of five biotechnology subsidiaries, from December 2019 to June 2023. Prior to this, she served as Vant Operating Chair at Roivant Sciences, Inc. from July 2018 to December 2019, where she oversaw thirteen biopharmaceutical companies with over thirty investigational drugs in eleven therapeutic areas. As Chief Executive Officer of Myrtle Potter & Company, LLC, Ms. Potter and her hand-picked team of experts led major strategic efforts and the preparation for multiple product launches for numerous biopharmaceutical companies. From 2000 to 2004, Ms. Potter served as Chief Operating Officer at Genentech, Inc., a biopharmaceutical company, and from 2004 to 2005, she served as the President, Commercial Operations and Executive Vice President of Genentech. Prior to joining Genentech, she held various positions, including President, U.S. Cardiovascular/Metabolics at Bristol-Myers Squibb, and Vice President at Merck & Co. While at Merck, she started the company Astra Merck, Inc. which later, through a series of transactions, became a part of AstraZeneca PLC. Ms. Potter currently serves on the Boards of Directors of Guardant Health Inc. and Liberty Mutual Holding Company, Inc. and the Board of Trustees of The University of Chicago. She has previously served on the Boards of Directors of Myovant Sciences, Ltd. from September 2018 to March 2023, Urovant Sciences Ltd. from July 2018 to March 2021, Axsome Therapeutics, Inc. from June 2017 to June 2020, Immunovant, Inc. from June 2019 to February 2020, Axovant Gene Therapies, Ltd. from September 2018 to February 2020, and Arbutus Biopharma, Inc. from October 2018 to February 2020, and Amazon.com, Inc. Ms. Potter holds a Bachelor of Arts Degree from The University of Chicago.
- Harry E. Sloan
-
Harry E. Sloan自2025年8月起担任联合董事长。Sloan先生自2024年6月起担任Bold Eagle的联合董事长，并在2021年3月至2024年6月期间担任该公司的董事长兼首席执行官。Sloan先生于2021年11月至2024年5月期间担任Screaming Eagle的董事长，直至Screaming Eagle完成与Lionsgate Studios Corp.的BINCE组合，Sloan先生继续担任Lionsgate Studios Corp.的董事。从2021年12月至2025年5月期间，Sloan先生担任独立电影和电视制作公司Lions Gate Entertainment Corp.（纽约证券交易所代码：LGF.A，LGF.B）（“Lions Gate Parent”）的董事会成员。从2011年2月至2013年1月完成与BINCE的组合，并且他仍然是合并后公司的董事，自2005年10月至2009年8月，Sloan先生担任电影、电视、家庭娱乐以及戏剧制作和发行公司Metro Goldwyn Mayer，Inc.（“MGM”）的董事长兼首席执行官，此后继续担任非执行董事长至2010年12月。MGM于2010年申请破产保护。从1990年到2002年，Sloan先生担任欧洲广播集团SBS Broadcasting，S.A.（“SBS”）的董事长兼首席执行官，在船尾和中东欧经营商业电视、付费频道、广播电台和相关印刷厂，他于1990年创立了这家公司，并继续担任执行董事长至2005年。1999年，SBS成为Lions Gate Parent的最大股东。Sloan先生于2004年4月至2005年3月担任Lions Gate Parent董事会主席。从1983年到1989年，Sloan先生是新世界娱乐有限公司的联合主席，这是一家独立的电影和电视制作公司。
Harry E. Sloan was previoly Chairman and Chief Executive Officer from March 2021 through June 2024. Mr. Sloan also serves as Co Chairman of Infinite Eagle Acquisition Corp.'s (Nasdaq: IEAG), or Infinite Eagle, a position he has held since Augt 2025.Mr. Sloan now serves as the Vice Chairman of DraftKings, Inc. Prior to Diamond Eagle, Mr. Sloan was a founding investor of Platinum Eagle, which raised $325,000,000 in its initial public offering in January 2018, completed its initial biness combination in March 2019 with Target Logistics Management, LLC and RL Signor Holdings, LLC and changed its name to Target Hospitality Corp. Target Hospitality Corp. (Nasdaq: TH) ("Target Hospitality") is a vertically integrated specialty rental and hospitality services company. Prior to Platinum Eagle, Mr. Sloan was a founding investor of Double Eagle, which raised $500,000,000 in its initial public offering in September 2015. Double Eagle completed its biness combination in November 2017, in which its wholly owned subsidiary acquired 90% of the shares of Williams Scotsman. In the transaction, Double Eagle changed its name to WillScot Corporation ("WSC"). WSC is a specialty rental services market leader providing modular space and portable storage solutions to diverse end markets across North America. Mr. Sloan previoly served as chairman and chief executive officer of Silver Eagle from April 2013 until the consummation of its initial biness combination in March 2015 with Videocon d2h Limited ("Videocon"). From May 2016 to April 2018 Mr. Sloan served on the board of directors of Videocon, where he was a member of its Nomination, Remuneration and Compensation Committee.Mr. Sloan was chairman and chief executive officer of SBS Broadcasting, S.A. ("SBS"), a European broadcasting group, operating commercial television, premium pay channels, radio stations and related print binesses in stern and Central and Eastern Europe, which he founded in 1990 and continued as executive chairman until 2005. In 1999, SBS became the largest shareholder of Lions Gate Parent. Mr. Sloan served as chairman of the board of Lions Gate Parent from April 2004 to March 2005. From 1983 to 1989, Mr. Sloan was co chairman of New World Entertainment Ltd., an independent motion picture and television production company. He previoly served on the boards of Promotora de Informaciones, S.A. (OTCMKTS: PRISY), Spain's largest media conglomerate, and ZeniMax Media Inc., an independent producer of interactive gaming and b content. - Harry E. Sloan自2025年8月起担任联合董事长。Sloan先生自2024年6月起担任Bold Eagle的联合董事长，并在2021年3月至2024年6月期间担任该公司的董事长兼首席执行官。Sloan先生于2021年11月至2024年5月期间担任Screaming Eagle的董事长，直至Screaming Eagle完成与Lionsgate Studios Corp.的BINCE组合，Sloan先生继续担任Lionsgate Studios Corp.的董事。从2021年12月至2025年5月期间，Sloan先生担任独立电影和电视制作公司Lions Gate Entertainment Corp.（纽约证券交易所代码：LGF.A，LGF.B）（“Lions Gate Parent”）的董事会成员。从2011年2月至2013年1月完成与BINCE的组合，并且他仍然是合并后公司的董事，自2005年10月至2009年8月，Sloan先生担任电影、电视、家庭娱乐以及戏剧制作和发行公司Metro Goldwyn Mayer，Inc.（“MGM”）的董事长兼首席执行官，此后继续担任非执行董事长至2010年12月。MGM于2010年申请破产保护。从1990年到2002年，Sloan先生担任欧洲广播集团SBS Broadcasting，S.A.（“SBS”）的董事长兼首席执行官，在船尾和中东欧经营商业电视、付费频道、广播电台和相关印刷厂，他于1990年创立了这家公司，并继续担任执行董事长至2005年。1999年，SBS成为Lions Gate Parent的最大股东。Sloan先生于2004年4月至2005年3月担任Lions Gate Parent董事会主席。从1983年到1989年，Sloan先生是新世界娱乐有限公司的联合主席，这是一家独立的电影和电视制作公司。
- Harry E. Sloan was previoly Chairman and Chief Executive Officer from March 2021 through June 2024. Mr. Sloan also serves as Co Chairman of Infinite Eagle Acquisition Corp.'s (Nasdaq: IEAG), or Infinite Eagle, a position he has held since Augt 2025.Mr. Sloan now serves as the Vice Chairman of DraftKings, Inc. Prior to Diamond Eagle, Mr. Sloan was a founding investor of Platinum Eagle, which raised $325,000,000 in its initial public offering in January 2018, completed its initial biness combination in March 2019 with Target Logistics Management, LLC and RL Signor Holdings, LLC and changed its name to Target Hospitality Corp. Target Hospitality Corp. (Nasdaq: TH) ("Target Hospitality") is a vertically integrated specialty rental and hospitality services company. Prior to Platinum Eagle, Mr. Sloan was a founding investor of Double Eagle, which raised $500,000,000 in its initial public offering in September 2015. Double Eagle completed its biness combination in November 2017, in which its wholly owned subsidiary acquired 90% of the shares of Williams Scotsman. In the transaction, Double Eagle changed its name to WillScot Corporation ("WSC"). WSC is a specialty rental services market leader providing modular space and portable storage solutions to diverse end markets across North America. Mr. Sloan previoly served as chairman and chief executive officer of Silver Eagle from April 2013 until the consummation of its initial biness combination in March 2015 with Videocon d2h Limited ("Videocon"). From May 2016 to April 2018 Mr. Sloan served on the board of directors of Videocon, where he was a member of its Nomination, Remuneration and Compensation Committee.Mr. Sloan was chairman and chief executive officer of SBS Broadcasting, S.A. ("SBS"), a European broadcasting group, operating commercial television, premium pay channels, radio stations and related print binesses in stern and Central and Eastern Europe, which he founded in 1990 and continued as executive chairman until 2005. In 1999, SBS became the largest shareholder of Lions Gate Parent. Mr. Sloan served as chairman of the board of Lions Gate Parent from April 2004 to March 2005. From 1983 to 1989, Mr. Sloan was co chairman of New World Entertainment Ltd., an independent motion picture and television production company. He previoly served on the boards of Promotora de Informaciones, S.A. (OTCMKTS: PRISY), Spain's largest media conglomerate, and ZeniMax Media Inc., an independent producer of interactive gaming and b content.
- Myrtle Potter
-
Myrtle Potter，2010年9月起，她担任公司董事会成员。2007年7月起，她担任私人咨询公司Myrtle Potter & Company, LLC的首席执行官和创始人。2009年8月起，她担任消费者医疗保健公司Myrtle Potter Media, Inc.的创始人和首席执行官。2005年6月至2012年7月，她担任Chapman Properties, Inc.的首席执行官， 该公司属于她拥有的一家不动产销售、融资和开发公司。2000年5月至2005年9月，她就职于生物技术公司Genentech, Inc.， 最近担任商业运营总裁。她目前是一流药店连锁Rite Aid Corporation和许多私人公司的董事会成员，过去5年间，她曾担任亚马逊（Amazon.com, Inc.）， Medco Health Solutions Inc.和Express Scripts Holding Co的董事会成员。她在芝加哥大学获得学士学位。
Myrtle Potter has served as a member of the Board since September 2018 and has served as the Chairman of the Board since November 2018. Ms. Potter has served as the Chief Executive Officer of Sumitovant Biopharma, Inc., a biopharmaceutical company and a subsidiary of Sumitovant Biopharma Ltd. since December 2019. From July 2018 to December 2019 Ms. Potter served as Vant Operating Chair of Roivant Sciences, Inc, a pharmaceutical company. Ms. Potter founded Myrtle Potter & Company, LLC, a private healthcare and life sciences advisory firm, in September 2005 and served as its Chief Executive Officer until June 2018. From August 2009 until December 2014 Ms. Potter served as Founder and Chief Executive Officer of Myrtle Potter Media, Inc., a consumer healthcare company. From 2000 to 2004 Ms. Potter served as Chief Operating Officer at Genentech, Inc., a biopharmaceutical company, and from 2004 to 2005 she served as its President, Commercial Operations and Executive Vice President. Prior to that, Ms. Potter held various positions, including President, U.S. Cardiovascular/Metabolics at Bristol-Myers Squibb and as a Vice President at Merck & Co. Ms. Potter currently serves on the board of directors of Liberty Mutual Holding Company Inc., a diversified global insurance company and several privately held companies, including Urovant Sciences Ltd., a biopharmaceutical company which ceased to be a public company in March 2021 as a result of Sumitovant acquiring all of the outstanding shares of Urovant not previously held by Sumitovant. Ms. Potter previously served on the boards of directors of Axsome Therapeutics, Inc., a biopharmaceutical company, from June 2017 to June 2020 Immunovant, Inc., a biopharmaceutical company, from December 2019 to February 2020 Axovant Gene Therapies Ltd., a biopharmaceutical company, from September 2018 to February 2020 Arbutus Biopharma Corporation, a biopharmaceutical company, from October 2018 to February 2020 INSMED Incorporated, a biopharmaceutical company, from December 2014 to November 2018 Rite Aid Corporation, a leading drugstore chain, from December 2013 to September 2018 Everyday Health, Inc., a leading provider of digital health and wellness solutions, from October 2010 until its acquisition in December 2016 and Amazon.com, Inc., a leading e-commerce company, from 2004 to 2009. She also served on the boards of directors of Medco Health Solutions Inc. and Express Scripts Holding Co., subsequent to its acquisition of Medco Health Solutions, as well as other privately held companies. Ms. Potter earned a B.A. from the University of Chicago. - Myrtle Potter，2010年9月起，她担任公司董事会成员。2007年7月起，她担任私人咨询公司Myrtle Potter & Company, LLC的首席执行官和创始人。2009年8月起，她担任消费者医疗保健公司Myrtle Potter Media, Inc.的创始人和首席执行官。2005年6月至2012年7月，她担任Chapman Properties, Inc.的首席执行官， 该公司属于她拥有的一家不动产销售、融资和开发公司。2000年5月至2005年9月，她就职于生物技术公司Genentech, Inc.， 最近担任商业运营总裁。她目前是一流药店连锁Rite Aid Corporation和许多私人公司的董事会成员，过去5年间，她曾担任亚马逊（Amazon.com, Inc.）， Medco Health Solutions Inc.和Express Scripts Holding Co的董事会成员。她在芝加哥大学获得学士学位。
- Myrtle Potter has served as a member of the Board since September 2018 and has served as the Chairman of the Board since November 2018. Ms. Potter has served as the Chief Executive Officer of Sumitovant Biopharma, Inc., a biopharmaceutical company and a subsidiary of Sumitovant Biopharma Ltd. since December 2019. From July 2018 to December 2019 Ms. Potter served as Vant Operating Chair of Roivant Sciences, Inc, a pharmaceutical company. Ms. Potter founded Myrtle Potter & Company, LLC, a private healthcare and life sciences advisory firm, in September 2005 and served as its Chief Executive Officer until June 2018. From August 2009 until December 2014 Ms. Potter served as Founder and Chief Executive Officer of Myrtle Potter Media, Inc., a consumer healthcare company. From 2000 to 2004 Ms. Potter served as Chief Operating Officer at Genentech, Inc., a biopharmaceutical company, and from 2004 to 2005 she served as its President, Commercial Operations and Executive Vice President. Prior to that, Ms. Potter held various positions, including President, U.S. Cardiovascular/Metabolics at Bristol-Myers Squibb and as a Vice President at Merck & Co. Ms. Potter currently serves on the board of directors of Liberty Mutual Holding Company Inc., a diversified global insurance company and several privately held companies, including Urovant Sciences Ltd., a biopharmaceutical company which ceased to be a public company in March 2021 as a result of Sumitovant acquiring all of the outstanding shares of Urovant not previously held by Sumitovant. Ms. Potter previously served on the boards of directors of Axsome Therapeutics, Inc., a biopharmaceutical company, from June 2017 to June 2020 Immunovant, Inc., a biopharmaceutical company, from December 2019 to February 2020 Axovant Gene Therapies Ltd., a biopharmaceutical company, from September 2018 to February 2020 Arbutus Biopharma Corporation, a biopharmaceutical company, from October 2018 to February 2020 INSMED Incorporated, a biopharmaceutical company, from December 2014 to November 2018 Rite Aid Corporation, a leading drugstore chain, from December 2013 to September 2018 Everyday Health, Inc., a leading provider of digital health and wellness solutions, from October 2010 until its acquisition in December 2016 and Amazon.com, Inc., a leading e-commerce company, from 2004 to 2009. She also served on the boards of directors of Medco Health Solutions Inc. and Express Scripts Holding Co., subsequent to its acquisition of Medco Health Solutions, as well as other privately held companies. Ms. Potter earned a B.A. from the University of Chicago.
高管简历
中英对照 | 中文 | 英文- Jason Kelly
Jason Kelly，我们的创始人之一，自2008年成立以来担任我们的董事会成员和首席执行官。Kelly博士曾担任CM Life Sciences IIInc.董事纳斯达克:CMII，一家专注于生命科学领域的特殊目的收购公司，自2021年2月首次公开募股以来。Kelly博士拥有麻省理工学院生物工程博士学位和化学工程和生物学学士学位。
Jason Kelly,one of our founders, has served as a member of our board of directors and as the Chief Executive Officer since Ginkgo’s founding in 2008. Dr. Kelly has served as a director of CM Life Sciences II Inc. Nasdaq: CMII, a special purpose acquisition company with a focus on the life sciences sector, since its initial public offering in February 2021. Dr. Kelly has a Ph.D. in Biological Engineering and a B.S. in Chemical Engineering and Biology from the Massachusetts Institute of Technology.- Jason Kelly，我们的创始人之一，自2008年成立以来担任我们的董事会成员和首席执行官。Kelly博士曾担任CM Life Sciences IIInc.董事纳斯达克:CMII，一家专注于生命科学领域的特殊目的收购公司，自2021年2月首次公开募股以来。Kelly博士拥有麻省理工学院生物工程博士学位和化学工程和生物学学士学位。
- Jason Kelly,one of our founders, has served as a member of our board of directors and as the Chief Executive Officer since Ginkgo’s founding in 2008. Dr. Kelly has served as a director of CM Life Sciences II Inc. Nasdaq: CMII, a special purpose acquisition company with a focus on the life sciences sector, since its initial public offering in February 2021. Dr. Kelly has a Ph.D. in Biological Engineering and a B.S. in Chemical Engineering and Biology from the Massachusetts Institute of Technology.
- Reshma Shetty
Reshma Shetty，我们的创始人之一，自2008年成立以来担任我们的董事会成员，总裁兼首席运营官。谢蒂博士目前在非营利组织“核威胁倡议”的生物咨询小组任职。谢蒂博士拥有麻省理工学院生物工程博士学位和犹他大学计算机科学学士学位。
Reshma Shetty,one of our founders, has served as a member of our board of directors and as President and Chief Operating Officer since Ginkgo’s founding in 2008. Dr. Shetty currently serves on the Bio Advisory Group at the non-profit Nuclear Threat Initiative. Dr. Shetty has a Ph.D. in Biological Engineering from the Massachusetts Institute of Technology and a B.S. in Computer Science from the University of Utah.- Reshma Shetty，我们的创始人之一，自2008年成立以来担任我们的董事会成员，总裁兼首席运营官。谢蒂博士目前在非营利组织“核威胁倡议”的生物咨询小组任职。谢蒂博士拥有麻省理工学院生物工程博士学位和犹他大学计算机科学学士学位。
- Reshma Shetty,one of our founders, has served as a member of our board of directors and as President and Chief Operating Officer since Ginkgo’s founding in 2008. Dr. Shetty currently serves on the Bio Advisory Group at the non-profit Nuclear Threat Initiative. Dr. Shetty has a Ph.D. in Biological Engineering from the Massachusetts Institute of Technology and a B.S. in Computer Science from the University of Utah.
- Steven Coen
Steven Coen于2023年5月1日加入公司，拥有超过30年的公共会计和公司财务领导经验，最近任职于Charles River Laboratories，这是一家面向制药和生物技术公司、政府机构和领先学术机构的全球合同研究组织，自2017年5月起担任公司副总裁兼公司财务总监。在加入Charles River之前，科恩在德勤会计师事务所（Deloitte & Touche LLP）从事审计业务超过17年后，曾在技术和医疗设备行业担任会计和财务领导职务。科恩先生在本特利大学获得会计学学士学位和管理学硕士学位，是马萨诸塞州的一名注册会计师。
Steven Coen,joined the Company on May 1, 2023 with over 30 years of public accounting and corporate finance leadership experience, most recently with Charles River Laboratories, a global contract research organization for pharmaceutical and biotechnology companies, government agencies and leading academic institutions, where he served as the Corporate Vice President & Corporate Controller since May 2017. Prior to Charles River, Mr. Coen served in accounting and finance leadership roles in the technology and medical device industries after spending more than 17 years in the audit practice at Deloitte & Touche LLP. Mr. Coen earned a B.S. in Accounting and an A.S. in Management from Bentley University and is a Certified Public Accountant in Massachusetts.- Steven Coen于2023年5月1日加入公司，拥有超过30年的公共会计和公司财务领导经验，最近任职于Charles River Laboratories，这是一家面向制药和生物技术公司、政府机构和领先学术机构的全球合同研究组织，自2017年5月起担任公司副总裁兼公司财务总监。在加入Charles River之前，科恩在德勤会计师事务所（Deloitte & Touche LLP）从事审计业务超过17年后，曾在技术和医疗设备行业担任会计和财务领导职务。科恩先生在本特利大学获得会计学学士学位和管理学硕士学位，是马萨诸塞州的一名注册会计师。
- Steven Coen,joined the Company on May 1, 2023 with over 30 years of public accounting and corporate finance leadership experience, most recently with Charles River Laboratories, a global contract research organization for pharmaceutical and biotechnology companies, government agencies and leading academic institutions, where he served as the Corporate Vice President & Corporate Controller since May 2017. Prior to Charles River, Mr. Coen served in accounting and finance leadership roles in the technology and medical device industries after spending more than 17 years in the audit practice at Deloitte & Touche LLP. Mr. Coen earned a B.S. in Accounting and an A.S. in Management from Bentley University and is a Certified Public Accountant in Massachusetts.